Freeman Gold Stock (OTC:FMANF), Trade Ideas

Freeman Gold Corp is a Canada-based mineral exploration and development company. The company primarily explores for gold. It is focused on the Lemhi gold project.

Cannabis

News

Penny Stocks

Entrepreneurship

Movers & Shakers

Small Cap

Markets

ECGI

FMANF

MCMJ

SPRWF

XXII

CSE:FMAN

TSX:FIRE

Leafly Hires Rebecca Warner As VP Of Sales

The cannabis information platform Leafly Holdings, Inc. said Wednesday that it has hired Rebecca Warner to serve as senior vice president of sales.

Cannabis Movers &amp; Shakers: Leafly, Origin Therapeutics, ECGI Holdings, 22nd Century Group

Will These Penny Stocks Perform Before The Weekend?

Top Penny Stocks To Watch Before Friday; 4 For Your List Right Now

Freeman Gold Corp

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday.
The Dow traded up 0.35% to 38,811.58 while the NASDAQ rose 0.95% to 16,309.74. The S&amp;P 500 also rose, gaining, 0.82% to 5,169.93.
Leading and Lagging Sectors Energy shares rose by 1.5% on Monday.
In trading on Friday, consumer staples shares fell by 0.4%.
Top Headline
Shares of Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) fell sharply during Monday&#8217;s session after reporting first-quarter results.
Spirit Airlines reported a first-quarter fiscal 2024 revenue decline of 6.2% Y/Y to $1.265 billion, marginally missing the consensus of $1.269 billion. Adjusted EPS loss was $(1.46), down from $(0.82), missing the consensus of $(1.45).
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Perficient, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFT#NASDAQ">PRFT</a>) shares shot up 53% to $73.38 after the company disclosed an acquisition deal and first-quarter FY24 results.</li>
<li>Shares of Strong Global Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGE#NYSE">SGE</a>) got a boost, surging 120% to $2.51  after FG Acquisition Corp. announced the proposed acquisition of Strong/MDI Screen Systems and the launch of Saltire Holdings.</li>
<li>XBP Europe Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBP#NASDAQ">XBP</a>) shares were also up, gaining 55% to $3.2680. XBP Europe Holdings was recently awarded a $40 million multi-year contract for a nationwide transformation project for His Majesty&#8217;s Passport Office.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Lyra Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares dropped 87% to $3.2680 after the company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.</li>
<li>Shares of GlycoMimetics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) were down 82% to $0.3330 after the company announced topline results from its Phase 3 global pivotal study of uproleselan in relapsed/refractory acute myeloid leukemia (R/R AML).</li>
<li>EyePoint Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) was down, falling 42% to $11.38 after the company&#8217;s Phase 2 PAVIA trial of DURAVYU did not meet its pre-specified primary endpoint.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/05/38641330/netflix-home-depot-and-more-on-cnbcs-final-trades">Netflix, Home Depot And More On CNBC&#8217;s &#8216;Final Trades&#8217;</a>
Commodities In commodity news, oil traded up 0.6% to $78.56 while gold traded up 1.1% at $2,333.60.
Silver traded up 3.6% to $27.66 on Monday, while copper rose 1.1% to $4.6085.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.53%, Germany's DAX rose 0.96% and France's CAC 40 gained 0.49%. Spain's IBEX 35 Index rose 0.58%, while London's FTSE 100 rose 0.51%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei falling 0.1%, Hong Kong's Hang Seng Index jumping 0.55% and India's S&amp;P BSE Sensex rising 0.02%.
Economics
No major economic reports will be released today.
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38641042/how-to-earn-500-a-month-from-fmc-stock-ahead-of-q1-earnings">How To Earn $500 A Month From FMC Stock Ahead Of Q1 Earnings</a>

Earnings

Eurozone

Commodities

Intraday Update

Trading Ideas

EYPT

GLYC

LYRA

PRFT

SAVE

Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge

dogwifhat's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) price has increased 4.31% over the past 24 hours to $3.37. Over the past week, WIF has experienced an uptick of over 28.0%, moving from $2.61 to its current price. As it stands right now, the coin's all-time high is $4.83. 
The chart below compares the price movement and volatility for dogwifhat over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715022143_0.png" alt="price_chart" />
The trading volume for the coin has increased 122.0% over the past week while the overall circulating supply of the coin has increased 0.25% to over 998.93 million which makes up an estimated 100.0% of its max supply, which is 998.93 million. The current market cap ranking for WIF is #36 at $3.39 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715022143_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$WIF

Cryptocurrency dogwifhat Up More Than 4% In 24 hours

Over the past 24 hours, Render's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">RNDR</a>) price rose 3.62% to $9.99. This continues its positive trend over the past week where it has experienced a 25.0% gain, moving from $7.72 to its current price. As it stands right now, the coin's all-time high is $13.53. 
The chart below compares the price movement and volatility for Render over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715022074_0.png" alt="price_chart" />
The trading volume for the coin has increased 236.0% over the past week. while the overall circulating supply of the coin has decreased 0.36% This puts its current circulating supply at an estimated 72.73% of its max supply, which is 532.07 million. The current market cap ranking for RNDR is #30 at $3.86 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715022074_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$RNDR

Cryptocurrency Render Rises More Than 3% In 24 hours

Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) has outperformed the market over the past 10 years by 2.75% on an annualized basis producing an average annual return of 13.25%. Currently, Agilent Technologies has a market capitalization of $41.33 billion. 
Buying $100 In A: If an investor had bought $100 of A stock 10 years ago, it would be worth $349.60 today based on a price of $141.02 for A at the time of writing.
<h3>Agilent Technologies's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715022070_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today

Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) has outperformed the market over the past 5 years by 21.34% on an annualized basis producing an average annual return of 33.67%. Currently, Antero Resources has a market capitalization of $10.67 billion. 
Buying $100 In AR: If an investor had bought $100 of AR stock 5 years ago, it would be worth $428.94 today based on a price of $34.31 for AR at the time of writing.
<h3>Antero Resources's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715022064_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today

Analysts' ratings for Newpark Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NR#NYSE">NR</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.75, a high estimate of $12.00, and a low estimate of $10.00. Witnessing a positive shift, the current average has risen by 7.5% from the previous average price target of $10.00.
<img src="https://www.benzinga.com/files/images/story/2024/1715022060_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Newpark Resources among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Rygiel</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Alex Rygiel</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>Gerry Sweeney</td>
<td>Roth MKM</td>
<td>Announces</td>
<td>Buy</td>
<td>$10.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Newpark Resources. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Newpark Resources compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Newpark Resources's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Newpark Resources analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Newpark Resources's Background</h2>
Newpark Resources Inc is a diversified supplier providing environmentally-sensitive products, as well as rentals and services to customers across multiple industries. The company has two operating segments: Industrial Solutions and Fluids Systems. Fluids Systems segment which generates the majority of the revenue, provides drilling, completion, and stimulation fluids products and related technical services to customers for oil, natural gas, and geothermal projects. Geographically, the company derives majority of its revenue from the United States and also has its presence in Canada, EMEA, Latin America, and Asia Pacific regions.
<h3>Newpark Resources's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Newpark Resources displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 0.77%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Newpark Resources's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.31%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Newpark Resources's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.74%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Newpark Resources's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.14%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Newpark Resources's debt-to-equity ratio is below the industry average. With a ratio of 0.23, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About Newpark Resources Stock

4 analysts have expressed a variety of opinions on Amneal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $7.81, along with a high estimate of $9.00 and a low estimate of $6.25. Marking an increase of 26.17%, the current average surpasses the previous average price target of $6.19. 
<img src="https://www.benzinga.com/files/images/story/2024/1715022051_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Amneal Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nathan Rich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$8.00</td>
<td>$6.25</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Nathan Rich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.25</td>
<td>$5.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amneal Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Amneal Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Amneal Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Amneal Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AMRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amneal Pharmaceuticals analyst ratings.</a>
<h2>About Amneal Pharmaceuticals</h2>
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
<h3>Amneal Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Amneal Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.18% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Amneal Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -15.99%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Amneal Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -56.27%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Amneal Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.76%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Amneal Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 139.05. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMRX

Assessing Amneal Pharmaceuticals: Insights From 4 Financial Analysts

Canaccord Genuity analyst Joseph Vafi maintains Iris Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Buy and maintains $9 price target.

Price Target

IREN

Canaccord Genuity Maintains Buy on Iris Energy, Maintains $9 Price Target

Throughout the last three months, 17 analysts have evaluated Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.82, with a high estimate of $38.00 and a low estimate of $20.00. Observing a downward trend, the current average is 2.73% lower than the prior average price target of $28.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1715022043_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Foot Locker's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$23.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$28.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Abbie Zvejnieks</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$27.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$28.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Abbie Zvejnieks</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Foot Locker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Foot Locker compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Foot Locker's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Foot Locker's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Foot Locker analyst ratings.</a>
<h2>All You Need to Know About Foot Locker</h2>
Foot Locker Inc operates thousands of retail stores throughout the United States, Canada, Europe, Asia, Australia, and New Zealand. It also has a presence in the Middle East. The company mainly sells athletically inspired shoes and apparel. Foot Locker's merchandise comes from only a few suppliers, with Nike providing the majority. Its portfolio of brands, includes Foot Locker, Kids Foot Locker, Champs Sports, WSS, and atmos. The company has omnichannel capabilities to bridge the digital world and physical stores, including order-in-store, buy online and pickup-in-store, and buy online and ship-from-store, as well as e-commerce. It has three operating segments, North America, EMEA, and Asia Pacific.
<h3>Financial Insights: Foot Locker</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Foot Locker displayed positive results in 3 months. As of 31 January, 2024, the company achieved a solid revenue growth rate of approximately 2.01%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -16.32%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Foot Locker's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -12.76%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Foot Locker's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.45%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 1.02, Foot Locker adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 17 Analyst Recommendations For Foot Locker

5 analysts have shared their evaluations of Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $44.6, a high estimate of $50.00, and a low estimate of $40.00. Marking an increase of 4.69%, the current average surpasses the previous average price target of $42.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1715022033_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Twist Bioscience. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$48.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Twist Bioscience. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Twist Bioscience compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Twist Bioscience's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Twist Bioscience's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TWST/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Twist Bioscience analyst ratings.</a>
<h2>Delving into Twist Bioscience's Background</h2>
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
<h3>Financial Milestones: Twist Bioscience's Journey</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Twist Bioscience's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 25.13%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Twist Bioscience's net margin excels beyond industry benchmarks, reaching -60.41%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Twist Bioscience's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -7.91%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -6.34%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.16, Twist Bioscience adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TWST

Breaking Down Twist Bioscience: 5 Analysts Share Their Views

In the preceding three months, 13 analysts have released ratings for Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $241.62, a high estimate of $270.00, and a low estimate of $212.00. Observing a 11.6% increase, the current average has risen from the previous average price target of $216.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1715022023_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Burlington Stores among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$218.00</td>
<td>$233.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$212.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$256.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$233.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Edward Yruma</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$270.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$252.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$230.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$225.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Burlington Stores. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Burlington Stores compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Burlington Stores's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Burlington Stores's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BURL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Burlington Stores analyst ratings.</a>
<h2>Discovering Burlington Stores: A Closer Look</h2>
Burlington Stores Inc is off-price retailer offering an extensive selection of in-season, fashion-focused merchandise including: women's ready-to-wear apparel, menswear, youth apparel, baby, beauty, footwear, accessories, home, toys, gifts and coats. Company sell a broad selection of desirable, first-quality, current-brand, labeled merchandise acquired directly from nationally recognized manufacturers and other suppliers. Company sell product in category such as Ladies apparel, Accessories and shoes, Home, Mens apparel, Kids apparel and baby and Outerwear.
<h3>Understanding the Numbers: Burlington Stores's Finances</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Burlington Stores's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.92% as of 31 January, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.28%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Burlington Stores's ROE excels beyond industry benchmarks, reaching 24.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Burlington Stores's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.99%, the company showcases efficient use of assets and strong financial health.
Debt Management: Burlington Stores's debt-to-equity ratio is notably higher than the industry average. With a ratio of 4.82, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BURL

Deep Dive Into Burlington Stores Stock: Analyst Perspectives (13 Ratings)

In the latest quarter, 9 analysts provided ratings for Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Remitly Global and provided 12-month price targets. The average target is $23.56, accompanied by a high estimate of $32.00 and a low estimate of $15.00. This upward trend is apparent, with the current average reflecting a 1.16% increase from the previous average price target of $23.29.
<img src="https://www.benzinga.com/files/images/story/2024/1715022013_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Remitly Global. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Gus Gala</td>
<td>Monness, Crespi, Hardt</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$19.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Remitly Global. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Remitly Global compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Remitly Global's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Remitly Global's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RELY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Remitly Global analyst ratings.</a>
<h2>About Remitly Global</h2>
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
<h3>Financial Milestones: Remitly Global's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Remitly Global's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 38.59%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Remitly Global's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -13.23%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -6.64%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.75%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.27.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RELY

The Analyst Landscape: 9 Takes On Remitly Global

Over the past 24 hours, XRP's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) price rose 3.53% to $0.55. This continues its positive trend over the past week where it has experienced a 7.0% gain, moving from $0.52 to its current price. As it stands right now, the coin's all-time high is $3.40. 
The chart below compares the price movement and volatility for XRP over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715022004_0.png" alt="price_chart" />
XRP's trading volume has climbed 44.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.18%. This brings the circulating supply to 55.24 billion, which makes up an estimated 55.24% of its max supply of 100.00 billion. According to our data, the current market cap ranking for XRP is #7 at $30.27 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715022004_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$XRP

XRP's Price Increased More Than 3% Within 24 hours

This past week, eight companies in&nbsp;KeyBanc&nbsp;analyst John Vinh&#8217;s semi-coverage universe reported, from which he highlighted vital takeaways. The companies included&nbsp;Advanced Micro Devices, Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>),&nbsp;Lattice Semiconductor Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>),&nbsp;Monolithic Power Systems, Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>),&nbsp;NXP Semiconductors NV&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>),&nbsp;ON Semiconductor Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>),&nbsp;Qualcomm Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>),&nbsp;Qorvo, Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>), and&nbsp;Skyworks Solutions, Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>).
He noted analog cyclical semis show incremental signs of stabilization and bottoming, with booking trends improving and channel inventory further decreasing.
Distributors&nbsp;Arrow Electronics, Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARW#NYSE">ARW</a>) and&nbsp;Avnet, Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVT#NASDAQ">AVT</a>) indicate that transportation in NA, A&amp;D in EUR, datacenter, and consumer in Asia showed signs of green shoots; however, guidance reflects incremental softness on more aggressive customer destocking trends.
Automotive is correcting, but&nbsp;with the exception of&nbsp;Tesla, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&nbsp;is&nbsp;not as bad as feared, while&nbsp;industrial appears further through the destocking process with indications of green shoots.
AI data centers remain robust, and traditional demand is gradually recovering, evidenced by new CPU platform ramps.
In conjunction with&nbsp;Apple Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) results and outlook, iPhone demand is mainly in line, with China&#8217;s better-than-feared and emerging market strength offsetting softer mature markets in RoW.&nbsp;
Also See:&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38613198" rel="noreferrer noopener">Apple Delivered Much Better-Than-Feared &#8216;Jalen-Brunson-Like&#8217; Quarter, Says Bullish Analyst: Why Betting Against Cupertino Is A &#8216;Wrong Move&#8217;</a>
Additionally, high-end Android demand remains strong, while the mass market segment is weak.&nbsp;
Looking into this week, Vinh has five companies scheduled to report. The companies include&nbsp;Arm Holdings Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>),&nbsp;Cirrus Logic, Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>),&nbsp;Indie Semiconductor, Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>),&nbsp;Microchip Technology Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>), and&nbsp;Synaptics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>).&nbsp;
He expects solid results for ARM and CRUS for the mobile and consumer supply chain.&nbsp;CRUS&#8217;s guidance could see modest risk due to high AAPL exposure, and ARM&nbsp;should&nbsp;benefit additionally&nbsp;from continuous share gains in cloud and AI licensing momentum and healthy demand for high-end handsets.&nbsp;
For SYNA, the analyst will seek in-line results and in-line slightly lower guidance, with lingering enterprise softness.&nbsp;
On analog, Vinh expects solid results and guidance for MCHP, similar to NXPI and&nbsp;Texas Instruments Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), with booking trends stabilizing and inventory normalizing further.&nbsp;
For Indie Semiconductor, Vinh projects in-line results and modest risks to guidance due to incremental auto weakness across both Internal Combustion Engine (ICE) Vehicle and Electric Vehicle (EV) (outside China).
Photo via Shutterstock

Analyst Color

Equities

Tech

AAPL

CRUS

INDI

LSCC

MCHP

MPWR

NXPI

QCOM

QRVO

SWKS

SYNA

TSLA

Thanks To Apple, This Analyst Is Optimistic On ARM, Microchip Technology And More Ahead Of Earnings

Monday,&nbsp;BioCryst Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) reported a first-quarter earnings loss of $(0.17) per share versus the consensus estimate loss of $(0.21) per share and $(0.28)&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g38637594/biocryst-reports-first-quarter-2024-financial-results-and-provides-business-update" rel="noreferrer noopener">reported a year ago</a>.
BioCryst Pharma reported sales of $92.8 million, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $85.61 million</a>. The sales increased 34.9% Y/Y, primarily due to $88.9 million in Orladeyo&#8217;s net revenue in the first quarter of 2024, up 30% Y/Y.
&#8220;We are off to a fantastic start to the year with outstanding Orladeyo revenue growth and our prioritized pipeline programs advancing on schedule. We are focused on continuing this momentum as we see strong patient demand for Orladeyo and more pipeline programs advancing into the clinic, starting later this year,&#8221; said Jon Stonehouse, president and CEO of BioCryst.
In the first quarter, the U.S. commercial team accelerated patients going through annual reimbursement reauthorization from free drug to paid drug faster than in previous years, generating higher than expected Orladeyo&nbsp;revenue.
New patient growth remained strong, with the past two quarters having the most new prescriptions in the United States since the first two quarters of the launch.
Sales from outside the U.S. contributed 10% of global Orladeyo net revenues in the first quarter, as the number of patients treated with Orladeyo continued to grow strongly and consistently in new and existing markets.&nbsp;
Guidance: BioCryst forecasts 2024 Orladeyo revenue Of $390 million -$400 million, the top end of its prior guidance of $380 milllion-$400 million.
The company expects full-year 2024 operating expenses to be between $365 million and $375 million, flat to full-year 2023 operating expenses.
BioCryst says it is even more confident that it will achieve a full-year operating profit in 2024, approach quarterly positive EPS and positive cash flow in the second half of 2025, and be profitable on an EPS basis with positive cash flow for 2026.
The company expects it can achieve these financial milestones without raising additional funds and does not intend to draw the additional $150 million of debt available to it from Pharmakon.
Price Action:&nbsp;BCRX shares are up 18.2% at $5.26 at last check Monday.

Biotech

Guidance

Health Care

General

BCRX

BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance

Legal

FAA Probing Boeing 787 Inspections, Whether Company Employees Falsified Records

Barrington Research analyst Alexander Paris maintains Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) with a Outperform and raises the price target from $13 to $14.

LINC

Barrington Research Maintains Outperform on Lincoln Educational Servs, Raises Price Target to $14

Scotiabank analyst Ben Isaacson maintains Mosaic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) with a Sector Outperform and lowers the price target from $40 to $38.

Scotiabank Maintains Sector Outperform on Mosaic, Lowers Price Target to $38

Scotiabank analyst Sung Ji Nam maintains Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) with a Sector Outperform and raises the price target from $43 to $48.

Scotiabank Maintains Sector Outperform on Twist Bioscience, Raises Price Target to $48

At the recent <a href="https://www.benzinga.com/events/cannabis-conference/fall-2024/">Benzinga Cannabis Capital Conference</a>, entrepreneur Luke Scarmazzo, who co-founded Prophet Brands, engaged deeply with attendees, exploring various avenues for collaboration. He emphasized his openness to diverse business ventures ranging from investments to licensing deals, revealing a strategic approach to leveraging industry connections.
<h3 class="wp-block-heading">Personal Journey And Advocacy</h3>
Scarmazzo, known for his nearly 15-year tenure in federal prison due to his early involvement in a state-legal cannabis dispensary, detailed the profound impact of his incarceration experience on his current advocacy efforts. He shed light on the reality that many still face imprisonment for non-violent cannabis crimes despite changing laws. Scarmazzo's narrative was not just his own. However, it echoed the lives of 3,000 others still behind bars, highlighting the urgent need for reform and support, which organizations like Mission Green actively address.
<h3 class="wp-block-heading">Future Goals And Projects</h3>
With an optimistic view of the future, Scarmazzo hinted at upcoming projects and partnerships that unfold in 2024 and 2025, though specifics remain confidential until these are finalized. His advocacy goals are equally ambitious, as he aspires to a future where his advocacy is no longer necessary—envisioning a time when no one will be incarcerated for cannabis offenses. On the business front, he discussed expanding his entrepreneurial ventures nationally and internationally, promising significant developments in the cannabis industry.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Luke Scarmazzo &#x7C; Prophet Brands" width="500" height="281" src="https://www.youtube.com/embed/5rP5yJYXRMc?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
<hr class="wp-block-separator has-alpha-channel-opacity" />
Cannabis rescheduling seems to be right around the corner. Want to understand what this means for the future of the industry? Hear directly for top executives, investors, and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a>&nbsp;before prices surge by following&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>. Image.
Photo: Courtesy of CRYSTALWEED cannabis via Unsplash

Events

Cannabis Reform Advocate Champions Change, Looks To Expand Prophet Across The Globe

Freeman Gold Corp (FMANF) has received a new Buy rating, initiated by Echelon Wealth Partners analyst, Gabriel Gonzalez CFA. Gabriel Gonzalez CFA h...

Promising Economic Assessment and Strong Returns Propel Freeman Gold Corp to a Buy Rating

Freeman Gold Corporation (TSE:FMAN) has released an update. Freeman Gold Corporation has engaged GSI Environmental Inc. to assist with the permitti...